New antibody combo aims to shrink Hard-to-Treat prostate tumors
NCT ID NCT05125016
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests two experimental drugs, REGN4336 and REGN5678, in men with metastatic castration-resistant prostate cancer that has worsened despite prior treatment. The first part finds safe doses, and the second part checks how well the combination shrinks tumors. About 228 participants will be enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
REGN4336 and REGN5678 (bispecific antibodies)
What this could lead to
If successful, this could provide a new treatment option for men with advanced prostate cancer that has stopped responding to standard therapies.
What could go wrong
This is an early-phase trial (Phase 1/2) with a small number of participants, so the drugs may not prove effective or may cause unexpected side effects. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Atrium Health Levine Cancer Institute
RECRUITINGCharlotte, North Carolina, 28204, United States
-
Fox Chase Cancer Center
WITHDRAWNPhiladelphia, Pennsylvania, 19111, United States
-
Fox Chase Cancer Center
RECRUITINGPhiladelphia, Pennsylvania, 19111, United States
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
Medical College of Wisconsin
RECRUITINGMilwaukee, Wisconsin, 53226, United States
-
Norton Cancer Institute
RECRUITINGLouisville, Kentucky, 40207, United States
-
Penn Medicine University of Pennsylvania Health System
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
-
Roswell Park Cancer Institute
RECRUITINGBuffalo, New York, 14263, United States
-
Rutgers Cancer Institute of New Jersey
RECRUITINGNew Brunswick, New Jersey, 08901, United States
-
Stanford University Medical Center - Blake Wilbur Drive
RECRUITINGPalo Alto, California, 94304, United States
-
The Ohio State University James Cancer Hospital
RECRUITINGColumbus, Ohio, 43210, United States
-
Thomas Jefferson University Hospital
RECRUITINGPhiladelphia, Pennsylvania, 19107, United States
-
University of Maryland Greenebaum Cancer Center
RECRUITINGBaltimore, Maryland, 21201, United States
-
Yale University Hospital
RECRUITINGNew Haven, Connecticut, 06510, United States